Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (April 2020)
20 slides from Adalta's investor presentation, Apr 30, 2020
Slide 1: i-bodies: next generation protein therapeutics solving difficult drug target challenges
For personal use only i-bodies: next generation protein therapeutics solving difficult drug target challenges April 2020 AdAlta Limited (ASX:1AD) Tim Oldham, CEO and Managing Director [email protected]
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: AdAlta's purpose
AdAlta’s purpose For personal use only “Next generation protein therapeutics” “Solving difficult drug target challenges” AdAlta Limited (ASX:1AD) is a late pre-clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug
Slide 4: AdAlta (ASX:1AD) summary
AdAlta (ASX:1AD) summary For personal use only i-body platform for generating multiple products against “difficult” targets – Internal pipeline focused on GPCRs implicated in fibrotic and inflammatory disease and cancer – External pipeline leveraging partner expertise to pursue wider range of target
Slide 5: Executive leadership
Executive leadership For personal use only Tim Oldham, PhD CEO & Managing Director • >20 years of international life sciences business development and commercialisation experience • Significant ASX listed company experience Mick Foley, PhD Claudia Gregorio-King, PhD Chief Scientific Officer VP Clini
Slide 6: AdAlta's strategy, business model to create value
AdAlta’s strategy, business model to create value For personal use only Strategy Revenue model In-house pipeline Licence to pharma of drug candidates Major upfronts + milestones AD-214 i-body products in defined & royalties ”sweet spot” Outcome Invest to value inflection G (typically Phase I or II)
Slide 7: Near term strategic priorities
Near term strategic priorities For personal use only Create value inflections for lead candidate AD-214 • Advance to clinic in Idiopathic Pulmonary Fibrosis • Expand indications and licensing options Build internal pipeline in our “sweet spot” • G-protein coupled receptors (GPCRs) • Fibrosis, inflam
Slide 8: Market opportunity for IPF (lung fibrosis)
Market opportunity for IPF (lung fibrosis) For personal use only Idiopathic Pulmonary Fibrosis (IPF) is an irreversible, unpredictable and incurable disease THE STATISTICS People living with IPF 300,000 People die from IPF every year 40,000 Median length of survival after IPF diagnosis 3.8 years 8 *
Slide 9: Significant recent AD-214 achievements
Significant recent AD-214 achievements A$1m BTB grant to Pre-clinical efficacy: mouse Pharmacokinetics and For personal use only radiolabel AD-214 for PET bleomycin model pharmacodynamics: non- imaging human primate 6 Receptor Occupancy - All animals Vehicle Statistical significance# to 21d bleomyci
Slide 10: Proposed two-part phase I design
SUBJECT TO ETHICS APPROVAL Proposed two-part phase I design For personal use only Phase I, dose-escalating study of the safety, tolerability, PK & PD of single and repeat doses of AD- 214 in healthy volunteers (HVs) and patients with interstitial lung disease (ILD) Part A (mid 2020) Part B (early 20
Slide 11: AdAlta's "sweet spot" facilitates more rapid screening of internal product ideas
AdAlta’s “sweet spot” facilitates more rapid screening of internal product ideas For personal use only 20 existing targets New ideas AdAlta’s internal development “sweet spot” – i-bodies to G-protein Coupled Receptors (GPCRs) Mechanism Need, indication • Clinically validated • Indications in fibrosi
Slide 12: AdAlta target pipeline evolution
SUBJECT TO FINANCE, TECHNICAL SUCCESS AdAlta target pipeline evolution Today For personal use only 2022 target Preclinical, IND Class of Partner Product/ Indication Discovery product enabling Phase I Phase II Target Target dev studies AD-214: Idiopathic CXCR4 GPCR Pulmonary Fibrosis AD-214: Indicati
Slide 13: Market benchmarks: Fibrosis
Market benchmarks Breaking: Jan-20 Boehringer Ingelheim and Enleofen ink $1 Billion+ fibrosis deal For personal use only Fibrosis Nov-19 acquired by Roche Sep-15 acquired by Roche Jul-19 license by Boehringer $390m + $1b – Phase II lead AD-214 $105m + $475m milestones Ingelheim €45m + €1.1b Aug-15 B
Slide 14: Growth trajectory to build value
Growth trajectory to build value C Timing and rate of growth For personal use only Accelerate dependent on financial resources (from ~mid-2021) AD-214 B • Phase I patient multi-dose + PET Expand • Phase I licensing window opens A (~mid 2020 to late 2021) • Next indication pre-clinical Maximise catal
Slide 15: Building a diversified, valuable pipeline
SUBJECT TO FINANCE Building a diversified, valuable pipeline Metric From AD-214 focus today … To multi-product by 2023 … For personal use only AD-214 development Pre-clinical in IPF Clinical in two indications Phase I partnering window Numerous milestones, inflection points Internal pipeline Substan
Slide 16: News flow
News flow Early 2020 For personal use only ü Patent granted covering AD-214 granted in the US ü Publication of role of CXCR4 in fibrosis ü Pre-clinical efficacy and PK/PD of AD-214 ü AdAlta strategy update (AD-214 clinical development and i-body platform growth) Mid-2020 – Ethics committee approval
Slide 17: Financial position and results: funded to end of Phase I health volunteer study
Financial position and results: funded to end of Phase I health volunteer study (late 2020) For personal use only Key financial details Share price performance (last 12 months) ASX code 1AD 0.25 5.0 Share price (29 April 2020) AUD$0.06 0.2 4.0 Market capitalisation AUD$9.84m Share Price (A$) Volume
Slide 18: International Board, Scientific Advisory Board
International Board, Scientific Advisory Board Extensive track record of drug, antibody development, capital raising and exits For personal use only Board Scientific Advisory Board Dr Paul MacLeman Dr Mick Foley Chair AdAlta CSO Expert in phage display Liddy McCall Director Brian Richardson Drug dis
Slide 19: AdAlta (ASX:1AD) summary
AdAlta (ASX:1AD) summary For personal use only i-body platform for generating multiple products against “difficult” targets – Internal pipeline focused on GPCRs implicated in fibrotic and inflammatory disease and cancer – External pipeline leveraging partner expertise to pursue wider range of target
Slide 20: Contact us
For personal use only Contact us: Tim Oldham, CEO and Managing Director [email protected] www.adalta.com.au